💊 Sri Lanka’s Pharmaceutical Sovereignity: SPMC Sets Ambitious Target of 10 New Drugs and 4 Billion Units for 2026
COLOMBO, SRI LANKA (January 4, 2026) — In a significant move toward national self-sufficiency in healthcare, the State Pharmaceuticals Manufacturing Corporation (SPMC) of Sri Lanka has officially announced a bold strategic plan for the year 2026. The corporation aims to introduce 10 brand-new pharmaceutical products to the local market while hitting a massive production milestone of 4,000 million tablets and capsules.
The announcement, released via an official statement earlier today, underscores the government’s commitment to reducing the nation’s reliance on expensive imported medicines and stabilizing the local supply chain.
🚀 Scaling Up: From 70 to 80 Essential Medicines
Currently, the SPMC manufactures approximately 70 different varieties of essential drugs, ranging from basic painkillers to complex treatments for chronic non-communicable diseases (NCDs). The addition of 10 new products this year will bring their total portfolio to 80, covering a wider spectrum of therapeutic needs for the Sri Lankan public.
The expansion is not just about variety but also volume. By targeting 4 billion units (tablets and capsules) for 2026, the SPMC is preparing to meet the rising demand within the government hospital network and the retail market.
🏆 2025: A Year of Shattered Records
The ambitious goals for 2026 come on the heels of what has been described as the most successful year in the history of the SPMC. Despite global logistics challenges and economic fluctuations, the corporation achieved unprecedented results in 2025:
- Record Production: Total production for 2025 reached a staggering 3,625 million tablets and capsules.
- Monthly Peak: March 2025 went down in history as the single most productive month ever for the corporation, with 385 million units manufactured in just 31 days.
- Product Innovation: Last year, five new pharmaceutical products were successfully introduced to the market.
- Flawless Supply Chain: The SPMC confirmed it fulfilled all orders placed by the Medical Supplies Division (MSD) without a single shortage—a critical feat for the stability of the free healthcare system.
💰 Financial Strength and Economic Impact
Beyond public health, the SPMC has proven to be a financially robust state-owned enterprise. According to the official communiqué, the corporation’s total revenue for 2025 reached a record Rs. 27.06 billion.
This financial success allows the SPMC to reinvest in high-tech machinery and Research and Development (R&D). Chairperson of the SPMC noted that the revenue growth is a testament to the trust doctors and patients place in “State-made” medicines, which are often priced significantly lower than private imports.
🏛️ The Vision: A Healthier, Self-Reliant Nation
The strategy for 2026 is part of a broader “Local Production of Pharmaceuticals” drive. By ramping up local manufacturing, Sri Lanka aims to:
- Save Foreign Exchange: Millions of dollars are currently spent on drug imports. Every tablet made in the Ratmalana or Kandy plants saves vital forex reserves.
- Price Control: Locally produced drugs act as a buffer against price hikes caused by currency depreciation.
- Emergency Readiness: Ensuring that essential medicines are always available, regardless of global shipping delays or international crises.
